Shares of small biotech firm Enzon were up about 5% today after the CEO announced that Lazard had been hired to look into potentially selling some or all of the company. Carl Icahn, who has a 13% stake in the company, also met with management to discuss something similar; shares have been down since he announced that meeting in late November. In this video, Motley Fool health care analyst David Williamson tells investors what kind of influence we can expect Icahn to have on shares as the company moves toward selling.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article This Biotech Is Officially for Sale originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.